Annual report
3937.TEDINET S100W4TV
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥5.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥5.2bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.3bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥1.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥936m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥877m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.3bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥919m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥858m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥526m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥574m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥832m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥624m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥858m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥526m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥7.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥6.9bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥5.8bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.6bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥4.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.3bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥2.2bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.1bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥3.8bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥2.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥931m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥727m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥821m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥874m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥922m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥19m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥273m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥111m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥203m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥61m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥126m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥155m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥447m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥152m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥76m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥71.13 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.73 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.68 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.38 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.25 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥71.11 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥44.15 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥47.57 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥68.49 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥51.75 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥456.77 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥395.82 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥348.19 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥322.44 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥249.28 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 70.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 16.8% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.0% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 14.5% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 24.6% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 24.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 977 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,088 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 1,065 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 947 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 935 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥3.8bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥2.9bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥1.8bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥737m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥154m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥359m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥226m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥233m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥88m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.1bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥342m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥341m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥177m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥384m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥200m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥4.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥3.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥2.5bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.0bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥683m | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥956m | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.4bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.3bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥2.1bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.7bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥792m | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥88.16 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.45 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.11 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥88.13 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥28.62 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥14.66 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥31.57 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥16.63 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥40 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥13 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥11 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥9 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥7 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥272.14 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥188.33 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥164.58 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥173.83 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥148.07 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 81.5% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.5% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.7% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 38.5% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.1% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 20.2% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 12,249,920 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,991,120 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,873,840 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,834,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,802,880 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 50 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 54 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 57 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 58 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 59 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 76
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥10m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥11m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥43m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥43m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥375m |
| Medical Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥9m |
| Medical Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥9m |
| Medical Businessreportable segment | employees | at 2025-03-31 | 44 pure |
| Medical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Medical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Medical Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥13m |
| Medical Businessreportable segment | segment assets | at 2025-03-31 | ¥2.8bn |
| Medical Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Technology Consultingreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥290m |
| Technology Consultingreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥177m |
| Technology Consultingreportable segment | employees | at 2025-03-31 | 924 pure |
| Technology Consultingreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥4.6bn |
| Technology Consultingreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.6bn |
| Technology Consultingreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥31m |
| Technology Consultingreportable segment | segment assets | at 2025-03-31 | ¥3.0bn |
| Technology Consultingreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥562m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥300m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥186m |
| —segment total | employees | at 2025-03-31 | 968 pure |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥6.4bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥6.3bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥43m |
| —segment total | segment assets | at 2025-03-31 | ¥5.8bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥300m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥186m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥43m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥5.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥600,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥600,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥300,000 |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥93m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥11m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥43m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥43m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥1.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥359m |
| Medical Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2m |
| Medical Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥11m |
| Medical Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Medical Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Medical Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥6m |
| Medical Businessreportable segment | segment assets | at 2024-03-31 | ¥2.7bn |
| Medical Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Technology Consultingreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥189m |
| Technology Consultingreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥154m |
| Technology Consultingreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥4.3bn |
| Technology Consultingreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.3bn |
| Technology Consultingreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥37m |
| Technology Consultingreportable segment | segment assets | at 2024-03-31 | ¥3.0bn |
| Technology Consultingreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥421m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥191m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥165m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥6.0bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥5.9bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥43m |
| —segment total | segment assets | at 2024-03-31 | ¥5.7bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥191m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥165m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥6.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥5.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥43m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥5.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Technology Consultingreportable segment | employees | at 2025-03-31 | 41 pure |
| —segment total | employees | at 2025-03-31 | 41 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,503
| Item | Context | Value | Unit |
|---|---|---|---|
| Total assets (5-year summary) | Prior1YearInstant | 6883815000 | JPY |
| Total assets (5-year summary) | CurrentYearInstant | 7870406000 | JPY |
| Net assets per share (5-year summary) | Prior4YearInstant | 249.28 | |
| Net assets per share (5-year summary) | Prior3YearInstant | 322.44 | |
| Net assets per share (5-year summary) | Prior2YearInstant | 348.19 | |
| Net assets per share (5-year summary) | Prior1YearInstant | 395.82 | |
| Net assets per share (5-year summary) | CurrentYearInstant | 456.77 | |
| Basic earnings loss per share (5-year summary) | Prior4YearDuration | 53.25 | |
| Basic earnings loss per share (5-year summary) | Prior3YearDuration | 70.38 | |
| Basic earnings loss per share (5-year summary) | Prior2YearDuration | 48.68 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 44.73 | |
| Basic earnings loss per share (5-year summary) | CurrentYearDuration | 71.13 | |
| Diluted earnings per share (5-year summary) | Prior4YearDuration | 51.75 | |
| Diluted earnings per share (5-year summary) | Prior3YearDuration | 68.49 | |
| Diluted earnings per share (5-year summary) | Prior2YearDuration | 47.57 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 44.15 | |
| Diluted earnings per share (5-year summary) | CurrentYearDuration | 71.11 | |
| Equity to asset ratio (5-year summary) | Prior4YearInstant | 0.663 | |
| Equity to asset ratio (5-year summary) | Prior3YearInstant | 0.678 | |
| Equity to asset ratio (5-year summary) | Prior2YearInstant | 0.706 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.682 | |
| Equity to asset ratio (5-year summary) | CurrentYearInstant | 0.704 | |
| Rate of return on equity (5-year summary) | Prior4YearDuration | 0.242 | |
| Rate of return on equity (5-year summary) | Prior3YearDuration | 0.246 | |
| Rate of return on equity (5-year summary) | Prior2YearDuration | 0.145 | |
| Rate of return on equity (5-year summary) | Prior1YearDuration | 0.120 | |
| Rate of return on equity (5-year summary) | CurrentYearDuration | 0.168 | |
| Price earnings ratio (5-year summary) | Prior4YearDuration | 57.7 | |
| Price earnings ratio (5-year summary) | Prior3YearDuration | 35.3 | |
| Price earnings ratio (5-year summary) | Prior2YearDuration | 42.6 | |
| Price earnings ratio (5-year summary) | Prior1YearDuration | 29.0 | |
| Price earnings ratio (5-year summary) | CurrentYearDuration | 18.0 | |
| Net cash provided by used in operating activities (5-year summary) | Prior4YearDuration | 921738000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior3YearDuration | 874138000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior2YearDuration | 820657000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 726899000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYearDuration | 930831000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior4YearDuration | -60522000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior3YearDuration | -202877000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior2YearDuration | -110510000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -272761000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYearDuration | 18799000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior4YearDuration | -76063000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior3YearDuration | -151537000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior2YearDuration | -447488000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -155016000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYearDuration | -126432000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior4YearInstant | 2773335000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior3YearInstant | 3342526000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior2YearInstant | 3636780000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |